Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Syrrx’s Structural Proteomics At Heart Of Pharmacia Alliance

Jan. 25, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

Triangle Plans NDA For One Drug, Discontinues Another

Jan. 22, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Jan. 16, 2002

By Aaron Lorenzo

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

Jan. 15, 2002

By Aaron Lorenzo

Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Jan. 14, 2002

By Aaron Lorenzo

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Jan. 9, 2002

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...